Auryxia
Total Payments
$12.6M
Transactions
34,330
Doctors
6,078
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $428,735 | 3,100 | 1,560 |
| 2023 | $1.3M | 2,266 | 1,108 |
| 2022 | $4.1M | 5,018 | 2,121 |
| 2021 | $788,388 | 6,332 | 2,477 |
| 2019 | $244,490 | 4 | 0 |
| 2018 | $4.0M | 10,341 | 2,824 |
| 2017 | $1.7M | 7,269 | 2,508 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $9.9M | 409 | 78.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $982,134 | 545 | 7.8% |
| Food and Beverage | $708,529 | 32,016 | 5.6% |
| Consulting Fee | $703,145 | 195 | 5.6% |
| Travel and Lodging | $353,977 | 964 | 2.8% |
| Space rental or facility fees (teaching hospital only) | $18,756 | 3 | 0.1% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $2,100 | 1 | 0.0% |
| Grant | $2,000 | 1 | 0.0% |
| Gift | $364.91 | 120 | 0.0% |
| Education | $151.69 | 76 | 0.0% |
Payments by Type
Research
$9.9M
409 transactions
General
$2.8M
33,921 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Determine the Effect of Ferric Citrate on Time to a Composite Endpoint of Initiation of Maintenance Dialysis or All-cause Mortality vs Placebo in Adults With Advanced CKD | AKEBIA THERAPEUTICS INC | $3.0M | 0 |
| KRX-0502 Ferric Citrate in Subjects With NDD-CKD and IDA The COMPASS Trial COMPASS | Keryx Biopharmaceuticals, Inc. | $1.9M | 0 |
| A Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Impact of Auryxia (Ferric Citrate) on Erythropoiesis-Stimulating Agent (ESA) Use, Intravenous (IV) Iron Use, Phosphate Control, and Anemia Control in Adult Participants on In-Center Hemodialysis or Home Dialysis | AKEBIA THERAPEUTICS INC | $1.8M | 0 |
| A 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease | AKEBIA THERAPEUTICS INC | $603,031 | 0 |
| Protocol 2014-FC-015 | Keryx Biopharmaceuticals, Inc. | $538,552 | 1 |
| 2015-FC-026 | Keryx Biopharmaceuticals, Inc. | $318,157 | 1 |
| Compass | Keryx Biopharmaceuticals, Inc. | $221,022 | 15 |
| Transition toFerric CitrateAmong Hemodialysis and Peritoneal Dialysis Patients | Keryx Biopharmaceuticals, Inc. | $218,426 | 0 |
| Ferric Citrate for the Transition From CKD Stage 45 to CKD Stage 5D 05D | Keryx Biopharmaceuticals, Inc. | $151,150 | 0 |
| CRIC-Visceral Adiposity and Physical Fitness in Chronic Kidney Disease CRIC-VAP | Keryx Biopharmaceuticals, Inc. | $133,692 | 0 |
| Outcomes of iron deficiency anemia in non-dialysis dependent chronic kidney disease | AKEBIA THERAPEUTICS INC | $129,032 | 0 |
| 2015-FC-022 | Keryx Biopharmaceuticals, Inc. | $122,747 | 1 |
| 2017-FC-45 | Keryx Biopharmaceuticals, Inc. | $100,000 | 0 |
| Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency | Keryx Biopharmaceuticals, Inc. | $98,739 | 0 |
| 2018-FC-049 | AKEBIA THERAPEUTICS INC | $94,757 | 0 |
| Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease PIOPKD | Keryx Biopharmaceuticals, Inc. | $94,757 | 0 |
| Effect of Ferric Citrate on ESA utilization in ESRD patients with high Ferritin & low transferrin saturation: A Pilot project | AKEBIA THERAPEUTICS INC | $73,648 | 0 |
| 2015-FC-033 | Keryx Biopharmaceuticals, Inc. | $50,265 | 1 |
| Ferric Citrate in ESRD Pilot Project | Keryx Biopharmaceuticals, Inc. | $49,099 | 0 |
| Impact of ferric citrate vs. ferrous sulfate on iron parameters and hemoglobin | AKEBIA THERAPEUTICS INC | $41,810 | 0 |
Top Doctors Receiving Payments for Auryxia — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Nephrology | New Bern, NC | $30,953 | 9 |
| , MD | Nephrology | Live Oak, TX | $29,552 | 51 |
| , MD, MPH | Cardiovascular Disease | Dallas, TX | $25,546 | 9 |
| , M.D | Nephrology | Asheville, NC | $24,586 | 4 |
| , MD | Nephrology | New York, NY | $24,000 | 40 |
| , M.D | Specialist | Great Neck, NY | $23,085 | 14 |
| , D.O | Nephrology | Troy, NY | $22,942 | 45 |
| , MD | Nephrology | Natchez, MS | $22,165 | 56 |
| , MD | Cardiovascular Disease | San Francisco, CA | $21,465 | 2 |
| , M.D | Internal Medicine | Mineola, NY | $20,902 | 12 |
| , MD | Nephrology | Louisville, KY | $20,686 | 17 |
| , M.D | Nephrology | Terre Haute, IN | $18,637 | 36 |
| , M.D | Nephrology | Houston, TX | $18,159 | 32 |
| , M.D | Nephrology | Torrance, CA | $18,015 | 21 |
| , MD | Nephrology | Orlando, FL | $17,761 | 28 |
| , MD | Nephrology | Lawrence, KS | $17,552 | 28 |
| , MD | Nephrology | Odessa, TX | $17,487 | 30 |
| , M.D | Nephrology | Honolulu, HI | $17,453 | 28 |
| , M.D., SC.D | Internal Medicine | Houston, TX | $17,415 | 8 |
| , M.D | Nephrology | Omaha, NE | $16,921 | 21 |
| , MD | Nephrology | Neenah, WI | $15,978 | 26 |
| , MBBS | Nephrology | Terre Haute, IN | $15,504 | 39 |
| , M.D | Nephrology | Newnan, GA | $14,651 | 48 |
| , M.D | Nephrology | Greenville, NC | $14,309 | 30 |
| , MD | Nephrology | Houston, TX | $13,580 | 57 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $12.6M
- Total Doctors 6,078
- Transactions 34,330
About Auryxia
Auryxia is a drug associated with $12.6M in payments to 6,078 healthcare providers, recorded across 34,330 transactions in the CMS Open Payments database. The primary manufacturer is AKEBIA THERAPEUTICS INC.
Payment data is available from 2017 to 2024. In 2024, $428,735 was paid across 3,100 transactions to 1,560 doctors.
The most common payment nature for Auryxia is "Unspecified" ($9.9M, 78.1% of total).
Auryxia is associated with 20 research studies, including "Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Determine the Effect of Ferric Citrate on Time to a Composite Endpoint of Initiation of Maintenance Dialysis or All-cause Mortality vs Placebo in Adults With Advanced CKD" ($3.0M).